Real-world safety and effectiveness of radium-223 (223Ra) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated in the US: The non-interventional REASSURE study

被引：0
|
作者：
Song, Daniel Y.
George, Saby
Zimberg, Shawn
Nordquist, Luke T.
Tomaszewski, Jeffrey
Conti, Peter S.
Meltzer, Jeffrey
Verholen, Frank
Schmall, Anja
Higano, Celestia S.
Sartor, A. Oliver
机构：
[1] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD USA
[2] Roswell Park Canc Inst, Buffalo, NY USA
[3] Adv Radiat Ctr New York, Lake Success, NY USA
[4] GU Res Network, Urol Canc Ctr, Omaha, NE USA
[5] MD Anderson Canc Ctr Cooper, Div Urol, Camden, NJ USA
[6] USC, Keck Sch Med, Mol Imaging Ctr, Los Angeles, CA USA
[7] Bayer Healthcare Pharmaceut Inc, Whippany, NJ USA
[8] Bayer Consumer Care, Basel, Switzerland
[9] Univ Washington, Seattle, WA 98195 USA
[10] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[11] Tulane Univ, Sch Med, Tulane Canc Ctr, 1430 Tulane Ave, New Orleans, LA 70112 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5050
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) sequentially treated with abiraterone acetate (AA) and radium-223 (RA223).
    Caffo, Orazio
    Frantellizzi, Viviana
    Tucci, Marcello
    Galli, Luca
    Monari, Fabio
    Baldari, Sergio
    Masini, Cristina
    Bortolus, Roberto
    Facchini, Gaetano
    Alongi, Pierpaolo
    Zichi, Clizia
    Biasco, Elisa
    Fanti, Stefano
    Pignata, Salvatore
    Filice, Angelina
    Borsatti, Eugenio
    Rossetti, Sabrina
    Spada, Massimiliano
    Cortesi, Enrico
    De Vincentis, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Fracture risk after radium-223 (Ra-223) in metastatic castration resistant prostate cancer (mCRPC).
    Alonzi, Roberto
    Parker, Chris C.
    Tunariu, Nina
    Koh, Dow-Mu
    Staffurth, John
    Blackledge, Matthew D.
    Padhani, Anwar R.
    Tree, Alison
    Stidwill, Helen
    Finch, Jessica
    Chatfield, Peter
    Perry, Sophie
    Tovey, Holly
    Hall, Emma
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] Safety and Effectiveness of Lutetium-177-Prostate-Specific Membrane Antigen (177Lu-PSMA) Therapy Used in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Radium-223 (223Ra): The RALU Study
    Rahbar, K.
    Essler, M.
    Eiber, M.
    La Fougere, C.
    Prasad, V.
    Fendler, W. P.
    Rassek, P.
    Hasa, E.
    Dittmann, H.
    Bundschuh, R. A.
    Pabst, K. M.
    Kurtinecz, M.
    Schmall, A.
    Verholen, F.
    Sartor, O.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S54 - S55
  • [24] Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    George, Daniel J.
    Sternberg, Cora N.
    Sartor, A. Oliver
    Saad, Fred
    Tombal, Bertrand F.
    Miller, Kurt
    Kalinovsky, Jan
    Jiao, XiaoLong
    Tangirala, Krishna
    Higano, Celestia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [25] Prognostic role of inflammatory biomarkers from peripheral blood and clinical factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra-223) (BIO-Ra-223 study).
    Rebuzzi, Sara Elena
    Bauckneht, Matteo
    Signori, Alessio
    Frantellizzi, Viviana
    Rizzini, Elisa Lodi
    Mascia, Manlio
    Lavelli, Valentina
    Stazza, Maria Lina
    Licari, Maria
    Donegani, Maria Isabella
    Ponzano, Marta
    Cavallini, Letizia
    Laghi, Viola
    Cindolo, Luca
    Costa, Renato Patrizio
    Spanu, Angela
    Rubini, Giuseppe
    Monari, Fabio
    De Vincentis, Giuseppe
    Fornarini, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer
    Kuppen, Malou C. P.
    Westgeest, Hans M.
    van der Doelen, Maarten J.
    van den Eertwegh, Alphonsus J. M.
    Coenen, Jules L. L. M.
    Aben, Katja K. H.
    van den Bergh, Alphons C. M.
    Bergman, Andries M.
    van den Bosch, Joan
    Celik, Filiz
    Hendriks, Mathijs P.
    Lavalaye, Jules
    van der Meer, Saskia
    Polee, Marco B.
    Somford, Diederik M.
    van Oort, Inge M.
    Uyl-de Groot, Carin A.
    Gerritsen, Winald R.
    FUTURE ONCOLOGY, 2020, 16 (19) : 1371 - 1384
  • [27] Radium-223 In The Treatment Of Metastatic Castration-Resistant Prostate Cancer
    Vazzana, C.
    Morano, S.
    Di Lascio, A.
    Grana, C.
    Chinol, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S880 - S880
  • [28] RADIUM-223: TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    James, D.
    Hillery, R.
    Freeman, L.
    Kumari, A.
    Kearney, N.
    INTERNAL MEDICINE JOURNAL, 2016, 46 : 30 - 31
  • [29] Symptomatic skeletal event (SSE) dynamics in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): An interim review of a prospective, noninterventional study (PARABO)
    Poeppel, T.
    Eschmann, S.
    Werner, A.
    Selkinski, I.
    Moellers, M-O.
    Neusser, T.
    Benson, A.
    Kalinovsky, J.
    Palmedo, H.
    ANNALS OF ONCOLOGY, 2018, 29 : 289 - +
  • [30] Clinical outcomes and treatment patterns in REASSURE : planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer
    Higano, Celestia S.
    George, Daniel J.
    Shore, Neal D.
    Sartor, Oliver
    Miller, Kurt
    Conti, Peter S.
    Sternberg, Cora N.
    Saad, Fred
    Sade, Juan Pablo
    Bellmunt, Joaquim
    Smith, Matthew R.
    Chandrawansa, Kumari
    Sandstroem, Per
    Verholen, Frank
    Tombal, Bertrand
    ECLINICALMEDICINE, 2023, 60
12345